{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T07:11:48Z","timestamp":1772608308876,"version":"3.50.1"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T00:00:00Z","timestamp":1731888000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.diabres.2024.111928","type":"journal-article","created":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T20:15:33Z","timestamp":1731442533000},"page":"111928","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Real world effectiveness of oral semaglutide: Focus on patients with type 2 diabetes older than 75\u00a0years"],"prefix":"10.1016","volume":"218","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4532-3028","authenticated-orcid":false,"given":"Walter","family":"Baronti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Lencioni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margherita","family":"Occhipinti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Nicolucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graziano Di","family":"Cianni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabres.2024.111928_b0005","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1111\/dom.14710","article-title":"Efficacy and safety of oral semaglutide by subgroups of patient characteristics in the PIONEER phase 3 programme","volume":"24","author":"Aroda","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2024.111928_b0010","unstructured":"European Medicines Agency (EMA) (2021) Human medicines highlights 2020 2021."},{"key":"10.1016\/j.diabres.2024.111928_b0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.conctc.2022.100944","article-title":"The efficacy and safety of oral semaglutide for glycaemic management in adults with type 2 diabetes compared to subcutaneous semaglutide, placebo, and other GLP-1 RA comparators: A systematic review and network meta-analysis","volume":"28","author":"Alhindi","year":"2022","journal-title":"Contemp Clin Trials Commun"},{"issue":"303\u20138","key":"10.1016\/j.diabres.2024.111928_b0020","article-title":"A significant effect of oral semaglutide on cardiovascular risk factors in patients with type 2 diabetes","volume":"13","author":"Yanai","year":"2022","journal-title":"Cardiol Res"},{"key":"10.1016\/j.diabres.2024.111928_b0025","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1111\/dom.15493","article-title":"Use of once-daily oral semaglutide and associated clinical outcomes among adults with type 2 diabetes in routine clinical practice in Canada: A multicentre, prospective real-world study (PIONEER REAL Canada)","volume":"26","author":"Jain","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2024.111928_b0030","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s13300-023-01525-y","article-title":"Real-World Use of Oral Semaglutide in Adults with Type 2 Diabetes: The PIONEER REAL Switzerland Multicentre, Prospective, Observational Study","volume":"15","author":"Kick","year":"2024","journal-title":"Diabetes Therapy"},{"key":"10.1016\/j.diabres.2024.111928_b0035","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1007\/s13300-023-01490-6","article-title":"Clinical Features, Cardiovascular Risk Profile, and Therapeutic Trajectories of Patients with Type 2 Diabetes Candidate for Oral Semaglutide Therapy in the Italian Specialist Care","volume":"14","author":"Morieri","year":"2023","journal-title":"Diabetes Therapy"},{"key":"10.1016\/j.diabres.2024.111928_b0040","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1111\/dom.14453","article-title":"Insights into the early use of oral semaglutide in routine clinical practice: The IGNITE study","volume":"23","author":"Aroda","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2024.111928_b0045","doi-asserted-by":"crossref","DOI":"10.1007\/s40618-024-02369-4","article-title":"Real-world use of oral versus subcutaneous semaglutide in a cohort of type 2 diabetic patients: which option to which patient?","author":"Formichi","year":"2024","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.diabres.2024.111928_b0050","doi-asserted-by":"crossref","first-page":"5102","DOI":"10.1007\/s12325-023-02677-w","article-title":"Real-World Hemoglobin A1c Changes, Prescribing Provider Types, and Medication Dose Among Patients with Type 2 Diabetes Mellitus Initiating Treatment with Oral Semaglutide","volume":"40","author":"Frazer","year":"2023","journal-title":"Adv Ther"},{"key":"10.1016\/j.diabres.2024.111928_b0055","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12186052","article-title":"Real-World Retrospective Study into the Effects of Oral Semaglutide (As a Switchover or Add-On Therapy) in Type 2 Diabetes","volume":"12","author":"Candido","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.diabres.2024.111928_b0060","doi-asserted-by":"crossref","DOI":"10.1007\/s40618-024-02309-2","article-title":"Effectiveness of oral semaglutide on glucose control and body weight up to 18 months: a multicenter retrospective real-world study","author":"Bonora","year":"2024","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.diabres.2024.111928_b0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2023.110672","article-title":"The AMD ANNALS: A continuous initiative for the improvement of type 2 diabetes care","volume":"199","author":"Russo","year":"2023","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.diabres.2024.111928_b0070","doi-asserted-by":"crossref","unstructured":"Mannucci E, Candido R, Monache L delle, Gallo M, Giaccari A, Masini ML, et al. 2023 update on Italian guidelines for the treatment of type 2 diabetes. Acta Diabetol 2023;60:1119\u201351. 10.1007\/s00592-023-02107-x.","DOI":"10.1007\/s00592-023-02107-x"},{"key":"10.1016\/j.diabres.2024.111928_b0075","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1111\/dom.15431","article-title":"Real-world effectiveness and safety of oral semaglutide in people living with type 2 diabetes: A nationwide multicentre retrospective observational study (ENDO2S-RWD)","volume":"26","author":"Moreno-P\u00e9rez","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2024.111928_b0080","article-title":"Retrospective Analysis of the Effectiveness of Oral Semaglutide in Type 2 Diabetes Mellitus and Its Effect on Cardiometabolic Parameters in Japanese Clinical Settings","volume":"10","author":"Yamada","year":"2023","journal-title":"J Cardiovasc Dev Dis"},{"key":"10.1016\/j.diabres.2024.111928_b0085","doi-asserted-by":"crossref","unstructured":"Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract 2022;183. 10.1016\/j.diabres.2021.109119.","DOI":"10.1016\/j.diabres.2021.109119"},{"key":"10.1016\/j.diabres.2024.111928_b0090","first-page":"331","article-title":"Diabetes Mellitus. Practical Issues in Geriatrics, vol. Part F12, Springer","author":"Mannucci","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.diabres.2024.111928_b0095","article-title":"Results of semaglutide in patients older than 70 years, a real-world study of efficacy and safety","author":"Lucas","year":"2023","journal-title":"Minerva Endocrinol"},{"key":"10.1016\/j.diabres.2024.111928_b0100","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1080\/00325481.2020.1800286","article-title":"Oral semaglutide in patients with type 2 diabetes and cardiovascular disease, renal impairment, or other comorbidities, and in older patients","volume":"132","author":"Mosenzon","year":"2020","journal-title":"Postgrad Med"},{"key":"10.1016\/j.diabres.2024.111928_b0105","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s13300-024-01551-4","article-title":"Real-World Use of Oral and Subcutaneous Semaglutide in Routine Clinical Practice in the UK: A Single-Centre","volume":"15","author":"Roy Chowdhury","year":"2024","journal-title":"Retrospect Observat Study Diabetes Ther"},{"key":"10.1016\/j.diabres.2024.111928_b0110","doi-asserted-by":"crossref","DOI":"10.1111\/jdi.14219","article-title":"PIONEER REAL Japan: Baseline characteristics of a multicenter, prospective, real-world study of oral semaglutide in adults with type 2 diabetes in clinical practice in Japan","author":"Suzuki","year":"2024","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.diabres.2024.111928_b0115","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1007\/s13300-024-01588-5","article-title":"Real-world use of oral semaglutide in adults with type 2 diabetes in the PIONEER REAL Netherlands multicentre, prospective, observational study","volume":"15","author":"van Houtum","year":"2024","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.diabres.2024.111928_b0120","doi-asserted-by":"crossref","unstructured":"Volpe S, Lisco G, Fanelli M, Racaniello D, Colaianni V, Lavarra V, et al. Oral semaglutide improves body composition and preserves lean mass in patients with type 2 diabetes: a 26-week prospective real-life study. Front Endocrinol (Lausanne) 2023;14. 10.3389\/fendo.2023.1240263.","DOI":"10.3389\/fendo.2023.1240263"},{"key":"10.1016\/j.diabres.2024.111928_b0125","doi-asserted-by":"crossref","DOI":"10.1177\/03000605231211402","article-title":"Efficacy, safety, and patient satisfaction with oral semaglutide: first single-centre clinical experience","volume":"51","author":"Jani\u0107","year":"2023","journal-title":"J Int Med Res"},{"key":"10.1016\/j.diabres.2024.111928_b0130","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1007\/s13300-024-01589-4","article-title":"Real-World Treatment Patterns Among Patients with Type 2 Diabetes Mellitus Initiating Treatment with Oral Semaglutide","volume":"15","author":"Swift","year":"2024","journal-title":"Diabetes Therapy"},{"key":"10.1016\/j.diabres.2024.111928_b0135","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1111\/dom.15516","article-title":"Real-world glycated haemoglobin changes among type 2 diabetes mellitus patients treated with a maintenance dose of 7 mg or 14 mg of oral semaglutide","volume":"26","author":"Swift","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2024.111928_b0140","article-title":"Oral Semaglutide on Glycemic Control and Weight Outcomes in Type 2 Diabetes (RELATE\u2013Oral Semaglutide)","volume":"72","author":"Amamoo","year":"2023","journal-title":"Diabetes"},{"key":"10.1016\/j.diabres.2024.111928_b0145","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1007\/s13300-024-01590-x","article-title":"Real-World Clinical Experience of Oral Semaglutide in a Secondary Diabetes Clinic in the UK: A Retrospective Observational Study","volume":"15","author":"Williams","year":"2024","journal-title":"Diabetes Therapy"},{"key":"10.1016\/j.diabres.2024.111928_b0150","doi-asserted-by":"crossref","unstructured":"Oe Y, Nomoto H, Yong Cho K, Yokozeki K, Ono T, Miya A, et al. Efficacy and safety of oral semaglutide in older patients with type 2 diabetes: a retrospective observational study (the OTARU-SEMA study) 2024. 10.21203\/rs.3.rs-3927633\/v1.","DOI":"10.21203\/rs.3.rs-3927633\/v1"},{"key":"10.1016\/j.diabres.2024.111928_b0155","doi-asserted-by":"crossref","DOI":"10.3390\/jcm13113054","article-title":"Oral Semaglutide in Routine Clinical Practice: Characteristics of People with Type 2 Diabetes Started on the Drug and Changes in Their Clinical Parameters after 24 Weeks of Treatment","volume":"13","author":"Baldassarre","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.diabres.2024.111928_b0160","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1111\/dom.15554","article-title":"Oral or injectable semaglutide for the management of type 2 diabetes in routine care: A multicentre observational study comparing matched cohorts","volume":"26","author":"Fadini","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2024.111928_b0165","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3390\/diabetology5010005","article-title":"Effectiveness of oral versus injectable semaglutide in adults with type 2 diabetes: results from a retrospective observational study in Croatia","volume":"5","author":"Klobu\u010dar","year":"2024","journal-title":"Diabetology"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822724008386?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822724008386?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T18:51:52Z","timestamp":1735671112000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822724008386"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":33,"alternative-id":["S0168822724008386"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2024.111928","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real world effectiveness of oral semaglutide: Focus on patients with type 2 diabetes older than 75\u00a0years","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2024.111928","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"111928"}}